Department of Oncology, Parc Taulí Sabadell Hospital Universitari, Sabadell, Barcelona, Spain.
Crit Rev Oncol Hematol. 2013 Nov;88(2):357-67. doi: 10.1016/j.critrevonc.2013.06.008. Epub 2013 Jul 16.
The term castration-resistant prostate cancer (CRPC) encompasses a wide variety of patients with different prognoses. The combination of docetaxel and prednisone is considered as the standard first-line chemotherapy. For years, patients progressing on docetaxel have been managed with second- and third-line hormone therapies, re-treatment with docetaxel, or combined mitoxantrone and prednisone. Recently published results of four studies using different drugs: cabazitaxel (CBZ), abiraterone (AA), enzalutamide (ENZ), and radium 223, showed an increased survival in such patients. In this article, authors make some considerations about criteria guiding the choice of a second-line chemotherapy after docetaxel in patients with metastatic CRPC, and propose an algorithm based on scientific evidence and consensus for rational use of cabazitaxel in this scenario.
去势抵抗性前列腺癌（CRPC）这一术语包含了预后不同的广泛的患者群体。多西他赛联合泼尼松被认为是标准的一线化疗药物。多年来，接受多西他赛治疗后进展的患者采用二线和三线激素治疗、重新使用多西他赛治疗或米托蒽醌联合泼尼松治疗。最近发表的四项研究结果使用了不同的药物：卡巴他赛（CBZ）、阿比特龙（AA）、恩扎鲁胺（ENZ）和镭 223，表明此类患者的生存率有所提高。在本文中，作者对转移性 CRPC 患者接受多西他赛后选择二线化疗的指导标准进行了一些思考，并根据科学证据和共识提出了一种在这种情况下合理使用卡巴他赛的算法。
